Calcium acetate
As of the edition of 20 October 2026, Calcium acetate is a small molecule: marketed, first approved in 1982 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Procalamine
- First approved
- 8 May 1982 (US)
- Approvals on record
- 6 in 1 region
- Holder of the most recent approval
- Fresenius Medical Care Renal Therapies; 2 holders in all
- Registered trials
- 14, 1 stopped early
- Disease areas
- Nutrition and metabolism; Pregnancy and women's health; Urinary and reproductive; Heart and blood vessels; Hormones; Infections
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 1 | 0 | 1 |
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 4 | 3 | 0 | 0 |
| Phase 4 | 5 | 5 | 0 | 0 |
| All trials | 14 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Fresenius Medical Care | Later holder and Lead sponsor of trials | 2008 to now |
| Fresenius Medical Care Renal Therapies | Acquired holder | 2025 to now |
| Braintree | Originator | 1990 to 2025 |